Intravenous immunoglobulin treatment in multiple sclerosis: A prospective, rater-blinded analysis of relapse rates during pregnancy and the postnatal period.
Alexander WinkelmannPaulus Stefan RommerMichael HeckerUwe Klaus ZettlPublished in: CNS neuroscience & therapeutics (2018)
In MS patients, IVIg treatment during and/or after delivery is an option to reduce the incidence of relapses during pregnancy and the postnatal period. Surprisingly, untreated patients becoming pregnant showed an increase in the relapse rate in the first trimester compared with the pre-gestational period. How alterations of hormone status during pregnancy affect disease activity in MS has to be further investigated.
Keyphrases
- multiple sclerosis
- end stage renal disease
- disease activity
- newly diagnosed
- ejection fraction
- rheumatoid arthritis
- chronic kidney disease
- systemic lupus erythematosus
- mass spectrometry
- pregnant women
- prognostic factors
- ms ms
- clinical trial
- high dose
- patient reported outcomes
- rheumatoid arthritis patients
- body mass index
- low dose
- weight loss
- weight gain
- atomic force microscopy
- high speed
- patient reported
- double blind